APSR2026-190

Yes
Late-Breaking
Submitted
Oral Presentation
AO19-003
 
 
https://storage.unitedwebnetwork.com/files/1285/1212877-46903-Oral AO19-003 - 08. Lung Cancer (Suko Hari A)_431525.pptx
Format: PPTX Only
 
Format: PDF Only
08. Lung Cancer
4

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Suko Hari Adiono * Airlangga University Pulmonology department, Medical Faculty Surabaya Indonesia
Resty Yudhawati Meliana - Airlangga University Pulmonology department, Medical Faculty Surabaya Indonesia
Anna Febriani - Airlangga University Pulmonology department, Medical Faculty Surabaya Indonesia
Munawaroh Fitriah - Airlangga University Clinical Pathology Department, Medical Faculty Surabaya Indonesia
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Suko
Hari Adiono
dr.sukoha.pulmonologist@gmail.com
+6282134249003
31-40
Indonesia
Original Research
ASSOCIATION BETWEEN HIGH MOBILITY GROUP BOX 1 (HMGB1) LEVELS AND PROGRESSION-FREE SURVIVAL IN STAGE IV NON-SMALL CELL LUNG CANCER PATIENTS
Maximum 25 words
Abstract Content
Background. Stage IV non-small cell lung cancer (NSCLC) remains associated with poor prognosis despite platinum-based chemotherapy. Identification of non-invasive biomarkers to predict clinical outcomes is essential. High Mobility Group Box 1 (HMGB1) is a stress-related inflammatory mediator implicated in tumor progression and chemotherapy resistance. Objective. To analyze the association between peripheral blood HMGB1 levels and progression-free survival (PFS) in stage IV NSCLC patients receiving platinum-based chemotherapy.
Methods. A prospective observational cohort study was conducted involving 33 stage IV NSCLC patients at Dr. Soetomo General Hospital, Surabaya, from December 2024 to December 2025. HMGB1 levels were measured before and after chemotherapy using ELISA. PFS was assessed based on RECIST 1.1 criteria. Statistical analysis included Wilcoxon test and Spearman correlation.
Results. Mean HMGB1 levels increased after chemotherapy (from 10.76 ± 12.21 ng/mL to 15.21 ± 16.17 ng/mL). Progressive disease occurred in 72.7% of patients, with a median PFS of 19.1 weeks. No significant correlation was found between pre- or post-chemotherapy HMGB1 levels and PFS. However, a significant negative correlation was observed between changes in HMGB1 levels (ΔHMGB1) and PFS (r = –0.403; p = 0.020), indicating that an increase in HMGB1 after chemotherapy was associated with shorter PFS.
Conclusion. Changes in peripheral HMGB1 levels following platinum-based chemotherapy are associated with progression-free survival in stage IV NSCLC patients, whereas absolute HMGB1 levels at a single time point are not. ΔHMGB1 may serve as a potential non-invasive prognostic biomarker in advanced lung cancer.
 
 
 
 
 
Yes
No
 
JPG or JPEG or PNG format ONLY
Non-small cell lung cancer, HMGB1, platinum-based chemotherapy, progression-free survival.
maximum 3 keywords and no abbreviations, separated by commas
None
246